Managing and treating Sydenham chorea: A systematic review
Brain and Behavior · 2023
DOI: 10.1002/brb3.3035 ↗At a glance
Systematische Übersicht in Brain and Behavior, 2023. Written by Samiuddin Tariq and 7 co-authors. Institution: Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. Major MEDLINE topics: Chorea. Cited 13 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Introduction
Sydenham's chorea (SC), prevalent in developing countries and occasionally affecting developed ones, poses a clinical challenge due to the lack of systematic guidelines for diagnosis and treatment. Resulting from Group A Beta‐Hemolytic Streptococcus infection, SC presents various symptoms. This review aims to collect and evaluate available data on SC management to propose a cohesive treatment plan.
Methods
We searched PubMed, the Cochrane Library, Google Scholar, and ClinicalTrials.gov for literature on SC management from inception until 24th July 2022. Studies were screened by titles and abstracts. Cochrane Collaboration's Risk of Bias tool (RoB‐1) assessed Randomized Controlled Trials, while the Risk of Bias In Non‐randomized Studies of Interventions (ROBINS‐I) tool evaluated nonrandomized studies.
Results
The review includes 11 articles assessing 579 patients. Excluding one study with 229 patients, of the remaining 550 patients, 338 (61.5%) were females. Treatments used were dopamine antagonists in 118 patients, antiepileptics in 198, corticosteroids in 134, IVIG in 7, and PE in 8 patients. Dopamine antagonists, particularly haloperidol, were the primary treatment choice, while valproic acid (VPA) was favored among antiepileptics. Prednisolone, a corticosteroid, showed promising results with weight gain as the only side‐effect. Our review emphasizes the importance of immunomodulators in SC, contrasting previous literature.
Conclusion
Despite limitations, dopamine antagonists can serve as first‐line agents in SC management, followed by antiepileptics. The role of immunomodulators warrants further investigation for conclusive recommendations.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
- Department of Internal Medicine, Wellstar Health System Spalding Hospital Griffin, Georgia, USA.
- Hamad Medical Corporation, Doha, Qatar.
- Kabir Medical College, Gandhara University, Peshawar Khyber Pakhtunkhkwa, Pakistan.
ORCID profiles: Faizan Niaz, Abdulqadir J Nashwan, Irfan Ullah
Cite
APA
Tariq, S., Niaz, F., Waseem, S., Shaikh, T. G., Ahmed, S. H., Irfan, M., Nashwan, A. J., & Ullah, I. (2023). Managing and treating Sydenham chorea: A systematic review. Brain and Behavior. https://doi.org/10.1002/brb3.3035
Vancouver
Tariq S, Niaz F, Waseem S, Shaikh TG, Ahmed SH, Irfan M, et al. Managing and treating Sydenham chorea: A systematic review. Brain and Behavior. 2023. doi:10.1002/brb3.3035
BibTeX
@article{Tariq2023,
author = {Tariq, Samiuddin and Niaz, Faizan and Waseem, Summaiyya and Shaikh, Taha Gul and Ahmed, Syed Hassan and Irfan, Muhammad and Nashwan, Abdulqadir J and Ullah, Irfan},
title = {Managing and treating Sydenham chorea: A systematic review},
journal = {Brain and Behavior},
year = {2023},
doi = {10.1002/brb3.3035}
}
EUVIMED